Skip to main content

Table 1 Characteristics of patients and first AE reported according to age group at onset of biological therapy

From: Influence of age on the occurrence of adverse events in rheumatic patients at the onset of biological treatment: data from the BIOBADASER III register

Variables

Young

Adult

Elderly

Very Elderly

p

N = 2483

63

2127

237

56

 

Age, mean (SD) in years

21.48 (4.48)

47.91 (9.98)

69.12 (2.87)

78.81 (3.10)

 

Female gender (%)

25 (39.68)

1163 (54.68)

171 (72.159)

42 (75.09)

< 0.001

Disease duration, mean (SD) in years

2.72 (3.39)

7.28 (7.68)

9.46 (9.40)

8.19 (8.95)

< 0.001

Duration of biologic treatment, mean (SD) in years

3.12 (3.409)

2.60 (3.14)

1.79 (2.18)

1.57 (1.95)

< 0.001

Diagnosis,n(%)

 RA, n = 1126

13 (1.15)

903 (80.20)

161 (14.30)

49 (4.35)

< 0.001

 PsA, n = 680

35 (5.15)

610 (89.71)

32 (4.71)

3 (0.44)

 AS, n = 677

15 (2.22)

614 (90.69)

44 (6.50)

4 (0.59)

Comorbidities

 Charlson Index, mean (SD)

1.02 (0.13)

1.25 (0.68)

1.81 (1.49)

2.07 (1.41)

< 0.001

 Tobacco: smokers/past smokers, n (%)

15 (23.81)

645 (30.32)

64 (27.00)

7 (12.50)

0.047

Concomitant immunosuppressive treatment,n(%) of use

 MTX

23 (41.8)

943 (53.61)

106 (55.79)

27 (60.00)

0.243

 Corticosteroids

15 (27.78)

806 (46.51)

129 (64.18)

33 (71.74)

< 0.001

 Initial corticoids dose (mg/day)

15.55 (16.26)

8.29 (7.24)

8.03 (5.85)

8.03 (6.37)

0.011

 Other

8 (12.70)

627 (29.48)

83 (35.02)

23 (41.07)

0.002

First AE (Total),n(%)

33 (52.4)

1227 (57.7)

147 (62.0)

37 (66.1)

 

 Infections

9 (27.27)

391 (31.87)

50 (34.01)

11 (29.73)

0.789

 Traumatic injuries

2 (6.06)

104 (8.48)

14 (9.52)

3 (8.11)

 Neoplasms

0 (0.00)

28 (2.28)

6 (4.08)

1 (2.70)

 Skin disorders

5 (15.15)

131 (10.68)

15 (10.20)

1 (2.70)

 Others

17 (51.52)

573 (46.70)

62 (42.18)

21 (56.76)

First severe AE,n(%)

4 (6.3)

138 (6.5)

36 (15.2)

11 (19.6)

 

 Infections

1 (25.00)

45 (32.61)

13 (36.11)

1 (9.09)

0.052

 Traumatic injuries

0 (0.00)

9 (6.52)

2 (5.56)

1 (9.09)

 Neoplasms

0 (0.00)

17 (12.32)

3.8 (8.33)

0 (0.00)

 Skin disorders

0 (0.00)

0 (0.00)

0 (0.00)

1 (9.09)

 Others

3 (75.00)

67 (48.55)

18 (50.00)

8 (72.73)

No AEn(%)

30 (47.6)

900 (42.3)

90 (38.0)

19 (33.9)

 
  1. AS ankylosing spondylitis, MTX methotrexate, PsA psoriatic arthritis, RA rheumatoid arthritis, TNF-i tumor necrosis factor inhibitor